# SERPIND1

## Overview
SERPIND1 is a gene that encodes the protein serpin family D member 1, also known as heparin cofactor II (HCII), which is a member of the serpin superfamily of serine protease inhibitors. This protein plays a critical role in the regulation of blood coagulation by inhibiting thrombin, a key enzyme in the coagulation cascade, thereby preventing excessive clot formation and maintaining hemostatic balance (Guo2019SERPIND1; Grover2022Anticoagulant). HCII's activity is significantly enhanced in the presence of glycosaminoglycans such as heparin, which induce conformational changes that increase its inhibitory efficacy (Grover2022Anticoagulant). The gene's function is essential for vascular homeostasis and has been implicated in various pathological conditions, including cancer and thrombotic disorders (Guo2019SERPIND1). Despite its critical role in coagulation, the clinical significance of SERPIND1 mutations in thrombotic diseases remains an area of active research (Wang2024The; Lee2017Wholeexome).

## Structure
The SERPIND1 gene encodes the protein heparin cofactor II (HCII), a member of the serpin superfamily. HCII is a serine protease inhibitor with a molecular weight of approximately 65 kDa (Grover2022Anticoagulant). The protein's structure is characterized by a conserved sequence of secondary structures, including three β-sheets and 8-9 α-helices, forming a core structural domain (Grover2022Anticoagulant). A critical feature of HCII is the reactive center loop (RCL), a 16-17 amino acid sequence that acts as molecular 'bait' for target proteases, allowing for the formation of a reversible Michaelis-Menten complex (Grover2022Anticoagulant).

HCII's inhibitory activity is enhanced upon binding to glycosaminoglycans (GAGs), which induce a conformational change that increases its activity towards target proteases like thrombin (Grover2022Anticoagulant). Unlike antithrombin, HCII can be activated by a variety of GAGs, including heparan sulfate, chondroitin sulfate, and dermatan sulfate (Grover2022Anticoagulant). The protein's native form is metastable, and its inhibition mechanism involves significant conformational changes upon interaction with target proteases (Gettins2016Inhibitory). The context does not provide specific details on the primary, tertiary, or quaternary structure, nor does it mention specific domains, prominent folds, post-translational modifications, or splice variant isoforms of SERPIND1.

## Function
SERPIND1 encodes a serine protease inhibitor known as antithrombin, which plays a crucial role in regulating blood coagulation. Antithrombin primarily functions in the bloodstream, where it inhibits thrombin and other proteases involved in the coagulation cascade, thereby preventing excessive clot formation and maintaining hemostatic balance (Chen2019Cloning). This regulation is essential for reducing the risk of thrombosis, a condition characterized by the formation of harmful blood clots within blood vessels.

In healthy human cells, SERPIND1 is involved in vascular homeostasis and the inhibition of thrombin activity through its interaction with heparin, which enhances its anticoagulant properties. This interaction is why SERPIND1 is also referred to as heparin cofactor II (Guo2019SERPIND1). The protein's activity is crucial for maintaining the delicate balance between coagulation and anticoagulation, ensuring that blood clots form only when necessary to prevent bleeding and are dissolved when no longer needed.

While the primary focus of research has been on its role in pathological conditions, such as cancer, SERPIND1's function in healthy cells is vital for normal physiological processes, particularly in the context of blood coagulation and vascular function (Guo2019SERPIND1).

## Clinical Significance
Mutations in the SERPIND1 gene, which encodes heparin cofactor II, have been associated with venous thromboembolism (VTE). A novel variant, R468C (R449C in the mature protein), was identified in a patient and is predicted to be deleterious to protein function. This mutation disrupts a critical contact with thrombin, potentially affecting the protein's ability to inhibit thrombin effectively (Lee2017Wholeexome). Another variant, c.G679A, p.R236H, was identified in a control patient, though its biological significance remains uncertain (Lee2017Wholeexome).

Despite these findings, the clinical evidence linking heparin cofactor II deficiency to VTE is not well-established. Some studies suggest that while endogenous and exogenous heparin cofactor II can inhibit arterial thrombosis, there is no strong clinical evidence supporting an association between its deficiency and VTE (Grover2022Anticoagulant). The role of SERPIND1 in cerebral venous thrombosis (CVT) has also been explored, but no direct link has been established, highlighting the need for further research (Wang2024The). Overall, while certain mutations in SERPIND1 may influence thrombotic risk, the clinical implications require further investigation.

## Interactions
SERPIND1, also known as heparin cofactor II, is a serine protease inhibitor that primarily interacts with thrombin, inhibiting its activity in the presence of glycosaminoglycans such as dermatan sulfate and heparin. This interaction is crucial for controlling thrombin's role in clot formation and maintaining hemostatic balance (Grover2022Anticoagulant). SERPIND1's activity is enhanced by binding to glycosaminoglycans, which induces a conformational change that increases its inhibitory activity. Unlike antithrombin, SERPIND1 is a stronger inhibitor of thrombin and has weaker activity against factor Xa (Grover2022Anticoagulant).

In the context of cancer, SERPIND1 has been shown to interact with components of the PI3K/AKT signaling pathway in epithelial ovarian cancer cells. Overexpression of SERPIND1 enhances the phosphorylation of PI3K and AKT, promoting cancer cell proliferation, migration, and invasion, while reducing apoptosis. These effects are mitigated by the PI3K inhibitor LY294002, indicating a regulatory interaction between SERPIND1 and the PI3K/AKT pathway (Guo2019SERPIND1). Additionally, NF-κB1 has been identified as a transcription factor that binds to the promoter region of SERPIND1, regulating its expression and suggesting a transcriptional interaction (Guo2019SERPIND1).


## References


[1. (Guo2019SERPIND1) Qian Guo, Liancheng Zhu, Caixia Wang, Shuang Wang, Xin Nie, Juanjuan Liu, Qing Liu, Yingying Hao, Xiao Li, and Bei Lin. Serpind1 affects the malignant biological behavior of epithelial ovarian cancer via the pi3k/akt pathway: a mechanistic study. Frontiers in Oncology, October 2019. URL: http://dx.doi.org/10.3389/fonc.2019.00954, doi:10.3389/fonc.2019.00954. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2019.00954)

[2. (Wang2024The) Shaoying Wang, Ming Yao, Xinzhuang Yang, Yicheng Zhu, and Bin Peng. The genetic risk factors for cerebral venous thrombosis: a case-control study in a chinese national comprehensive hospital. Thrombosis Journal, June 2024. URL: http://dx.doi.org/10.1186/s12959-024-00621-8, doi:10.1186/s12959-024-00621-8. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12959-024-00621-8)

[3. (Lee2017Wholeexome) Eun-Ju Lee, Daniel J. Dykas, Andrew D. Leavitt, Rodney M. Camire, Eduard Ebberink, Pablo García de Frutos, Kavitha Gnanasambandan, Sean X. Gu, James A. Huntington, Steven R. Lentz, Koen Mertens, Christopher R. Parish, Alireza R. Rezaie, Peter P. Sayeski, Caroline Cromwell, Noffar Bar, Stephanie Halene, Natalia Neparidze, Terri L. Parker, Adrienne J. Burns, Anne Dumont, Xiaopan Yao, Cassius Iyad Ochoa Chaar, Jean M. Connors, Allen E. Bale, and Alfred Ian Lee. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances, 1(16):1224–1237, June 2017. URL: http://dx.doi.org/10.1182/bloodadvances.2017005249, doi:10.1182/bloodadvances.2017005249. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1182/bloodadvances.2017005249)

[4. (Gettins2016Inhibitory) Peter G.W. Gettins and Steven T. Olson. Inhibitory serpins. new insights into their folding, polymerization, regulation and clearance. Biochemical Journal, 473(15):2273–2293, July 2016. URL: http://dx.doi.org/10.1042/bcj20160014, doi:10.1042/bcj20160014. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bcj20160014)

[5. (Grover2022Anticoagulant) Steven P. Grover and Nigel Mackman. Anticoagulant serpins: endogenous regulators of hemostasis and thrombosis. Frontiers in Cardiovascular Medicine, May 2022. URL: http://dx.doi.org/10.3389/fcvm.2022.878199, doi:10.3389/fcvm.2022.878199. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcvm.2022.878199)

[6. (Chen2019Cloning) Liangming Chen, Rong Huang, Denghui Zhu, Yumeng Wang, Rumana Mehjabin, Yongming Li, Lanjie Liao, Libo He, Zuoyan Zhu, and Yaping Wang. Cloning of six serpin genes and their responses to gcrv infection in grass carp (ctenopharyngodon idella). Fish &amp; Shellfish Immunology, 86:93–100, March 2019. URL: http://dx.doi.org/10.1016/j.fsi.2018.11.008, doi:10.1016/j.fsi.2018.11.008. This article has 11 citations.](https://doi.org/10.1016/j.fsi.2018.11.008)